Stockscreener 앱 받기
3.70
2.21%
0.08
전일 마감가:
$3.62
열려 있는:
$3.62
하루 거래량:
269.39K
Relative Volume:
0.28
시가총액:
$323.52M
수익:
$32.77M
순이익/손실:
$-101.98M
주가수익비율:
-0.385
EPS:
-9.6101
순현금흐름:
$-112.43M
1주 성능:
-7.50%
1개월 성능:
-0.27%
6개월 성능:
+143.42%
1년 성능:
-73.26%
1일 변동 폭
$3.585
$3.755
1주일 범위
$3.56
$4.00
52주 변동 폭
$1.35
$24.43
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
명칭
X 4 Pharmaceuticals Inc
전화
857-529-8300
주소
61 NORTH BEACON STREET, BOSTON, MA
XFOR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.70 | 316.52M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-05 | 재개 | Stifel | Buy |
| 2023-12-12 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 재개 | B. Riley Securities | Buy |
| 2022-12-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | ROTH Capital | Buy |
| 2019-12-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-12-05 | 개시 | B. Riley FBR | Buy |
| 2019-06-07 | 개시 | Stifel | Buy |
| 2019-06-05 | 개시 | Cowen | Outperform |
모두보기
X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31% - Yahoo Finance Singapore
Quarterly Trades: Is AXSPRE attractive at current valuationWeekly Gains Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ten new Xenon hires receive 42,300 stock options vesting over 4 years - Stock Titan
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by PGGM Investments - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC - MarketBeat
Layoff Tracker: Lyra Shutters, EMD Serono Downsizes - BioSpace
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Could Be Riskier Than It Looks - simplywall.st
Market Recap: What Wall Street predicts for X4 Pharmaceuticals Inc stock priceBear Alert & Accurate Buy Signal Alerts - Bộ Nội Vụ
Gains Report: How X4 Pharmaceuticals Inc stock reacts to inflationary pressuresM&A Rumor & Consistent Profit Trading Strategies - Bộ Nội Vụ
Aug Fed Impact: Can X4 Pharmaceuticals Inc stock deliver 10 annual returnsWeekly Stock Recap & AI Based Buy/Sell Signal Reports - Bộ Nội Vụ
p-Chip Corporation, Choice One Rx, and RxERP Launch Precedent-Setting Trial Demonstrating Digital Traceability of Drug Supply Chains and Chain-of-Identity for DSCSA Compliance, Co-Sponsored by Avantor - Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy - Yahoo Finance
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - BioSpace
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Yahoo Finance
Why X4 Pharmaceuticals Inc. stock remains resilientQuarterly Risk Review & Daily Oversold Stock Bounce Ideas - ulpravda.ru
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug By Investing.com - Investing.com South Africa
Why X4 Pharmaceuticals Inc. (48Q0) stock fits value portfoliosJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - Улправда
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Can X4 Pharmaceuticals Inc. stock deliver sustainable ROEInsider Selling Patterns & Investment Risk Management Tips - Улправда
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of “Hold” by Analysts - Defense World
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Analysts - MarketBeat
What drives X4 Pharmaceuticals Inc 48Q0 stock priceAnalyst Upgrades & Free Powerful Profit Generation - earlytimes.in
Torrent Pharma board gives nod to Rs 12,500-crore bond issue - TradingView — Track All Markets
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Prescription Drug Costs - Britannica
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
What drives X4 Pharmaceuticals Inc stock pricePrice Momentum Alerts & Free Trading Signals to Sharpen Your Edge - earlytimes.in
4,485 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Calamos Advisors LLC - MarketBeat
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Grows By 27.1% - Defense World
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire
Short Covering: Why X4 Pharmaceuticals Inc 48Q0 stock is a strong buy callJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - moha.gov.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Cwm LLC - MarketBeat
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat
174,077 Shares in Crinetics Pharmaceuticals, Inc. $CRNX Purchased by Rice Hall James & Associates LLC - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? - Finviz
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon - simplywall.st
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch
IndMoney and Federal Bank Savings AccountBull Market Opportunities & Subscribe for Free Weekly Winners - Bollywood Helpline
Will X4 Pharmaceuticals Inc. (48Q0) stock boost dividends further2025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Will X4 Pharmaceuticals Inc. stock continue upward momentumEarnings Trend Report & Safe Entry Trade Signal Reports - Улправда
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans - MarketBeat
X 4 Pharmaceuticals Inc (XFOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
X 4 Pharmaceuticals Inc 주식 (XFOR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
4.73%
0.92%
자본화:
|
볼륨(24시간):